INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently closed to accrual) * QBS10072S
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem glejaka mózgu lub gliosarcoma po operacji chirurgicznej
- •Wiek co najmniej 18 lat
- •Dobry ogólny stan zdrowia (ocena Karnofsky'ego ≥60)
- •Prawidłowa funkcja wątroby, nerek i szpiku kostnego
- •Zdolność do połykania tabletek
- •Planowany początek radioterapii 14-42 dni po operacji
- •Dostępne wyniki badań genetycznych tumozu
- •Badanie MRI z wzmacniaczem wykonane w ciągu 21 dni przed leczeniem
✗ Disqualifies
- •Glejak zlokalizowany w dolnej części mózgu (poniżej namiotka móżdżku)
- •Poprzednia chemioterapia lub radioterapia tego nowotworu
- •Niezdolność do przełknięcia tabletek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 19, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (12)
University of Alabama at Birmingham
Birmingham, United States
Massachusetts General Hospital
Boston, United States
Dana Farber Cancer Institute
Boston, United States
Mayo Clinic
Rochester, United States
Columbia University Medical Center
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Cleveland Clinic
Cleveland, United States
University of Pittsburgh Medical Center
Pittsburgh, United States
Lifespan / Rhode Island Hospital
Providence, United States
UT MD Anderson Cancer Center
Houston, United States
Huntsman Cancer Institute
Salt Lake City, United States
University of Virginia Health System
Charlottesville, United States
Trial contact
David Y Reardon, MD
David Reardon
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/20/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.